Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
314 stopped studies mapped to Kidney Carcinoma and descendants · 86% state a reason
Over the 314 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01198158 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer… | Phase 3 | terminated | Sep 9, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02867332 | PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma. | Phase 1 | withdrawn | Aug 15, 2016 | Peking University | No funding | Funding |
| NCT01502228 | PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma | N/A | terminated | Dec 30, 2011 | Indiana University | No further funding | Funding |
| NCT01115803 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | Phase 1 | terminated | May 4, 2010 | Eli Lilly and Company | Primary objective has been met; safety and pharmacokinetics have been characterized. | Safety / toxicity |
| NCT03323710 | Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell… | Phase 2 | withdrawn | Oct 27, 2017 | Military Institute od Medicine National Research Institute | Poor patient recruitment. | Enrollment / accrual |
| NCT01441414 | PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated… | Phase 2 | terminated | Sep 27, 2011 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT02026960 | RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal… | N/A | terminated | Jan 3, 2014 | Duke University | The sponsor's clinical program for the agent used in this study was discontinued. | Other (stated, no rule matched) |
| NCT01740154 | Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer | N/A | terminated | Dec 4, 2012 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | Phase 2 | terminated | Aug 4, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or… | Phase 3 | withdrawn | Oct 3, 2018 | Hoffmann-La Roche | In the context of the ongoing evaluation of our data, we have determined that there is no need to… | Safety / toxicity |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination…(RENALVax-2) | Phase 2 | withdrawn | Jul 21, 2017 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | No patients enrolled due to change in standard practice | Enrollment / accrual |
| NCT02560012 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Phase 2 | terminated | Sep 25, 2015 | The University of Texas Health Science Center, Houston | Loss of laboratory performing molecular analysis | Other (stated, no rule matched) |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus… | Phase 2 | withdrawn | May 5, 2016 | Bristol-Myers Squibb | Insufficient enrollment | Enrollment / accrual |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT01642095 | Studying Biomarkers in Samples From Younger Patients With Kidney Cancer | — | withdrawn | Jul 17, 2012 | Children's Oncology Group | not stated | Not stated |
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell… | Phase 1 | terminated | Mar 11, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | Phase 1 / Phase 2 | terminated | Apr 22, 2015 | Western Regional Medical Center | Investigator no longer at site to enroll patients or write up data | Investigator |
| NCT01482949 | A Rollover Protocol for Subjects Previously Treated With AGS-003 | Phase 2 | terminated | Dec 1, 2011 | Argos Therapeutics | Lack of efficacy | Efficacy / futility |
| NCT02626754 | A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell… | Phase 2 | terminated | Dec 10, 2015 | vghtpe user | In most sites had difficult to recruitting subjects. | Enrollment / accrual |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation… | Phase 2 | withdrawn | May 11, 2017 | Medical University of South Carolina | This study is withdrawn due to feasibility issues. | Other (stated, no rule matched) |
| NCT01582672 | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of…(ADAPT) | Phase 3 | terminated | Apr 23, 2012 | Argos Therapeutics | Lack of efficacy | Efficacy / futility |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Phase 1 | terminated | Sep 7, 2015 | Celldex Therapeutics | Portfolio re-prioritization | Sponsor / business decision |
| NCT02747173 | Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and…(METHEOS) | — | terminated | Apr 21, 2016 | Spanish Oncology Genito-Urinary Group | not stated | Not stated |
| NCT03456401 | Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)(TOKIO) | Phase 2 | terminated | Mar 7, 2018 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | availability of new and more promising therapeutic agents than expected in the experimentation in… | Other (stated, no rule matched) |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma… | Phase 2 | withdrawn | Nov 11, 2016 | University of Kansas Medical Center | Due to competing trials. Stopped before IRB approval. | Other (stated, no rule matched) |
| NCT02338570 | Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With…(ORCHIDEE) | Phase 4 | terminated | Jan 14, 2015 | Mario Negri Institute for Pharmacological Research | Stopped on November 16th 2016, because of recruitment failure. | Enrollment / accrual |
| NCT01762592 | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With… | Phase 3 | withdrawn | Jan 7, 2013 | Heidelberg Pharma AG | new sponsor | Other (stated, no rule matched) |
| NCT02370342 | Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small… | N/A | withdrawn | Feb 24, 2015 | University of Southern California | No funding | Funding |
| NCT02122003 | Second Line Sorafenib After Pazopanib in Patients With RCC(SOAP) | Phase 2 | terminated | Apr 24, 2014 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | availability of new and more promising therapeutic agents than expected in the experimentation in… | Other (stated, no rule matched) |
| NCT00158886 | Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer | Phase 1 | terminated | Sep 12, 2005 | GlaxoSmithKline | not stated | Not stated |
| NCT02138578 | Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal… | N/A | terminated | May 14, 2014 | University of Michigan Rogel Cancer Center | Due to changes in scanning procedure, and infeasible biopsy and baseline imaging, the trial closed… | Enrollment / accrual |
| NCT01492192 | RGD-PET-CT in Cancer Angiogenesis | Phase 2 | terminated | Dec 14, 2011 | Oxford University Hospitals NHS Trust | not stated | Not stated |
| NCT01784978 | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m…(SUNRISES) | Phase 2 | terminated | Feb 6, 2013 | Associació per a la Recerca Oncologica, Spain | Lack of recruitment | Enrollment / accrual |
| NCT02089802 | Optimizing Pazopanib Exposure in RCC Patients(OPERA) | Phase 2 | terminated | Mar 18, 2014 | Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e. | Early termination due to lack of recruitment | Enrollment / accrual |
| NCT01598038 | Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal… | N/A | terminated | May 15, 2012 | Centre Francois Baclesse | not stated | Not stated |
| NCT02928263 | Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma… | — | withdrawn | Oct 10, 2016 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of… | Phase 1 / Phase 2 | withdrawn | Aug 6, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00934440 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal…(5-AZ) | Phase 1 / Phase 2 | terminated | Jul 8, 2009 | University of Kansas Medical Center | not stated | Not stated |
| NCT01599832 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib… | N/A | terminated | May 16, 2012 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT00651482 | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001… | Phase 2 | terminated | Apr 2, 2008 | Sandy Srinivas | slow accrual | Enrollment / accrual |
| NCT02071641 | Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Feb 26, 2014 | Amsterdam UMC, location VUmc | not stated | Not stated |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem… | Phase 2 | terminated | Jun 17, 2008 | University of Arizona | Pentostatin/alemtuzumab regimen had greater risk of graft failure. | Other (stated, no rule matched) |
| NCT01943188 | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With… | Phase 1 | terminated | Sep 16, 2013 | Stanford University | not stated | Not stated |
| NCT01441765 | PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | Phase 2 | terminated | Sep 28, 2011 | Beth Israel Deaconess Medical Center | Funding | Funding |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT00672178 | Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic,… | Phase 1 / Phase 2 | terminated | May 6, 2008 | Duke University | Slow accrual | Enrollment / accrual |
| NCT01712685 | Imaging Studies of Kidney Cancer Using 18F-VM4-037 | Phase 2 | terminated | Oct 23, 2012 | National Cancer Institute (NCI) | Study was closed to accrual because imaging agent was no longer available. | Enrollment / accrual |
| NCT02410174 | To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma… | Phase 1 | terminated | Apr 7, 2015 | Beth Israel Medical Center | Poor Accural | Other (stated, no rule matched) |
| NCT01144169 | Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma | Phase 1 | terminated | Jun 15, 2010 | University of Pittsburgh | barriers to accrual: delay until surgery and additional pre-operative visits | Enrollment / accrual |
| NCT00061178 | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | Phase 3 | withdrawn | May 23, 2003 | Genentech, Inc. | No patients were enrolled, study cancelled before start | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 6, 2019source: clinicaltrials